For a homeless patient unable to store insulin who is on insulin glargine 10 units daily, sitagliptin 25 mg daily, and dapagliflozin 5 mg daily with blood glucose 123–344 mg/dL, how should the basal insulin be discontinued and what oral regimen should be used?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Discontinue Lantus and Maximize Oral Agents with Close Monitoring

For this homeless patient unable to store insulin, discontinue the Lantus 10 units daily and intensify the oral regimen by increasing sitagliptin to 100 mg daily while continuing dapagliflozin 5 mg daily, with metformin added if not contraindicated. This patient's blood glucose range of 123-344 mg/dL indicates inadequate control that requires medication intensification, not just insulin discontinuation 1.

Rationale for Insulin Discontinuation

The patient is on a very low dose of basal insulin (10 units daily, likely <0.15 U/kg), which suggests either early insulin requirement or poor baseline control. Given the social circumstances preventing insulin storage in the shelter, continuing insulin poses both practical impossibility and safety risks 1.

Recommended Oral Regimen

Immediate Changes:

  • Increase sitagliptin from 25 mg to 100 mg daily - The current 25 mg dose is subtherapeutic. Standard dosing is 100 mg daily, which provides superior glycemic control without hypoglycemia risk 2, 3

  • Continue dapagliflozin 5 mg daily - This SGLT2 inhibitor provides glucose-lowering without hypoglycemia risk and offers cardiovascular benefits. However, educate the patient about diabetic ketoacidosis warning signs and ensure adequate hydration access, as homelessness increases DKA risk 4, 5

  • Add metformin 500-1000 mg twice daily (if renal function permits and no contraindications) - Metformin remains first-line therapy and works synergistically with DPP-4 inhibitors and SGLT2 inhibitors 1, 3

Critical Safety Considerations

SGLT2 Inhibitor Precautions in Homeless Patients:

The FDA label explicitly warns to withhold dapagliflozin in situations predisposing to ketoacidosis 4. In homeless patients, specific concerns include:

  • Unpredictable food intake - increases DKA risk
  • Limited access to hydration - increases volume depletion risk
  • Poor genital hygiene facilities - increases genital mycotic infection risk (9% incidence) 4
  • Difficulty recognizing/reporting symptoms - delays treatment of complications

Despite these risks, dapagliflozin can be continued given its efficacy and the patient's current tolerance, but requires explicit counseling about stopping the medication and seeking care if experiencing nausea, vomiting, abdominal pain, or decreased oral intake 4, 5.

Expected Outcomes

This triple oral combination (metformin + sitagliptin + dapagliflozin) can achieve:

  • HbA1c reduction of 1.0-1.5% from baseline 3
  • Fasting glucose reduction of 15-30 mg/dL 6, 7
  • Weight reduction of 1-2 kg (beneficial given likely obesity) 8, 9
  • Minimal hypoglycemia risk (<1% severe hypoglycemia) 1, 3

Monitoring Plan

  • Check blood glucose at shelter or clinic weekly initially to assess response
  • Target glucose <180 mg/dL fasting, <200 mg/dL postprandial as realistic goals 1
  • Reassess in 2-4 weeks - if glucose remains >300 mg/dL consistently, insulin will be unavoidable and alternative housing/storage solutions must be found 1
  • Monitor for genital infections, urinary symptoms, and volume depletion given SGLT2 inhibitor use 4

Alternative if Oral Regimen Fails

If blood glucose remains severely elevated (consistently >300 mg/dL) after 2-4 weeks on maximized oral therapy, this patient will require insulin regardless of housing status 1. In this scenario:

  • Coordinate with social services for insulin storage solutions (clinic-based administration, day programs, case management)
  • Consider once-weekly GLP-1 agonist as alternative injectable if available and affordable
  • Basal insulin 0.2-0.3 U/kg daily would be indicated for severe hyperglycemia >300 mg/dL 1

Common Pitfall to Avoid

Do not simply discontinue insulin without intensifying oral agents - this patient's glucose of 344 mg/dL indicates the current regimen (Januvia 25 mg + Farxiga 5 mg) is grossly inadequate. The sitagliptin dose is only 25% of the therapeutic dose, leaving substantial room for oral intensification before accepting uncontrolled hyperglycemia 2, 3.

References

Guideline

management of diabetes and hyperglycaemia in the hospital.

The Lancet Diabetes and Endocrinology, 2021

Related Questions

How should I manage a patient with hemoglobin A1c 7.3% (previously 7.5%) who is on dapagliflozin (Farxiga) 10 mg daily and metformin 500 mg twice daily?
For an adult with type 2 diabetes needing additional glucose lowering, should I use Januvia (sitagliptin) or Farxiga (dapagliflozin)?
Can I give metformin XR (Glumet XR) 500 mg once daily after dinner with dapagliflozin 10 mg after breakfast, and increase metformin XR to 1000 mg (two tablets) after dinner if glucose remains elevated after one month?
For a 30‑year‑old male with cystic fibrosis‑related diabetes on total parenteral nutrition (200 g dextrose over 24 h) receiving 30 U NPH (neutral protamine Hagedorn) with methylprednisolone 36 mg at 08:00 and 7 U regular insulin in the TPN, with an insulin‑sensitivity factor of 25, how should the NPH dose and the TPN regular insulin dose be adjusted when methylprednisolone is reduced to 32 mg at 08:00?
In a 59-year-old male with type 2 diabetes, weight 117 kg, currently on insulin glargine (Lantus) 80 units daily and receiving continuous TPN from 8 pm to 8 am containing 300 g dextrose with 123 units of regular insulin, insulin sensitivity factor 10 mg/dL per unit, insulin‑to‑carbohydrate ratio 4 g/unit, and fasting blood glucose values of 177, 209, 226, 215, and 261 mg/dL overnight, what should the basal insulin (insulin glargine) dose and the regular insulin amount in the TPN be adjusted to?
Which apolipoprotein is considered the "bad" one that promotes atherosclerosis?
Can exposure to vapors, gases, dust, fumes (vapour‑gas‑dust‑fume), solvents, heavy metals, and gasoline cause hypertension, and what is the typical latency for its onset?
What is the appropriate initial management for a 35‑year‑old healthy male who experiences frequent palpitations after a 20‑hour travel day, has occasional premature atrial contractions (PAC) and premature ventricular contractions (PVC) on ECG/Holter, a normal echocardiogram, and no associated symptoms such as light‑headedness, chest pain, or shortness of breath?
What is the appropriate treatment for a C6 disc bulge causing headache and neck pain?
What are the benefits of atorvastatin?
Is Breztri (budesonide/formoterol/glycopyrrolate) available for adult patients with asthma?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.